Equal-WT
WhaleScore 2.0
?
PERCEPTIVE ADVISORS LLC
NEW YORK NY
Investment Advisor
Hedge Fund
Activist Investor
Perceptive Advisors is based out of New York and is run by Joseph Edelman. Perceptive Advisors is a hedge fund with 29 clients and discretionary assets under management (AUM) of $9,715,749,804 (Form ADV from 2024-08-08). Their last reported 13F filing for Q1 2025 included $2,838,202,794 in managed 13F securities
and a top 10 holdings concentration of 54.4%. Perceptive Advisors's largest holding is Verona Pharma Plc with shares held of 6,563,340. Whalewisdom has at least 130 13F filings, 117 13D filings, 532 13G filings, and 87 Form 4 filings
Investment Strategy
The funds aim to generate superior returns while preserving capital by investing and trading primarily in U.S. equities within the biotechnology sector. They may invest in various securities, including stocks, bonds, options, futures, and derivatives, and may engage in short selling and margin trading. There is no limit to the amount of assets that can be invested in any particular position or strategy, and the approach emphasizes securities of companies in the biotechnology industry.
The investment strategy employs a two-pronged approach, analyzing biotech stocks based on both perception and reality. The advisor attempts to maximize investment opportunities related to changes in investor perception, such as the expectancy of FDA approval for a new drug. Simultaneously, the advisor analyzes the underlying products of biotech securities, considering factors like the effectiveness of drugs in clinical trials, FDA approval, and sales success. The advisor anticipates actively trading securities to achieve optimal returns in the biotech sector.
Owners
- EDELMAN, JOSEPH, ERIC - CHIEF EXECUTIVE OFFICER AND PORTFOLIO MANAGER
- MANNIX, JAMES, HENRY - CHIEF OPERATING OFFICER
- RAKITIN, ALEXANDER, NMN - CHIEF COMPLIANCE OFFICER
- FIERRO, PETER, WILLIAM - CHIEF FINANCIAL OFFICER
- ROSNER, MARCEL, TREBOUX - GENERAL COUNSEL Click on the Ownership/Private Fund Data tab for more details.
Other Contact Information
(Subscription Required)
2025-03-31
Top Buys (13F)
| Name | % Change |
|---|---|
| VRNA Verona Pharma Plc | 6.5% |
| EWTX Edgewise Therapeutic | 3.1% |
| SLNO Soleno Therapeutics | 1.93% |
| INSM Insmed Inc | 1.1% |
| BBNX Beta Bionics Inc. | 0.95% |
2025-03-31
Top Sells (13F)
| Name | % Change |
|---|---|
| IOVA Iovance Biotherapeut | 3.02% |
| PCVX Vaxcyte, Inc | 2.94% |
| NUVL Nuvalent Inc | 1.57% |
| PRAX Praxis Precision Med | 1.51% |
| CNTA Centessa Pharmaceuti | 1.39% |
2025-03-31
13F Holdings Summary
| Name | $ Change |
|---|---|
| VRNA Verona Pharma Plc | 14.68% |
| ACLX Arcellx Inc | 6.76% |
| FOLD Amicus Therapeutics | 6.17% |
| EWTX Edgewise Therapeutic | 5.08% |
| RYTM Rhythm Pharmaceutica | 4.76% |
2025-03-31
13F Activity
| Market Value | $2.84b, Prior: $3.63b |
| Inflows (Outflows) as % of Total MV | (-13.3354)% |
| New Purchases | 16 stocks |
| Added To | 15 stocks |
| Sold out of | 28 stocks |
| Reduced holdings in | 28 stocks |
| Top 10 Holdings % | 54.4% |
| Turnover %[1] | 38.26% |
| Turnover Alt %[2] | 13.23% |
| Time Held Top 20 | 6.85 quarters |
| Time Held Top 10 | 6.8 quarters |
| Time Held All | 8.61 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2025-03-31
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2025-03-31
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2025-03-31